株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のギラン・バレー症候群市場(免疫グロブリン静注、血漿交換法、その他(鎮痛剤、抗痙攣剤、LMWH) - 世界の業界分析、規模、シェア、成長、動向、予測(2017~2025年)

Guillain-Barre Syndrome Market (Intravenous Immunoglobulin, Plasma Exchange, Others (Analgesics, Anticonvulsants, LMWH)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

発行 Transparency Market Research 商品コード 641002
出版日 ページ情報 英文 194 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
世界のギラン・バレー症候群市場(免疫グロブリン静注、血漿交換法、その他(鎮痛剤、抗痙攣剤、LMWH) - 世界の業界分析、規模、シェア、成長、動向、予測(2017~2025年) Guillain-Barre Syndrome Market (Intravenous Immunoglobulin, Plasma Exchange, Others (Analgesics, Anticonvulsants, LMWH)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日: 2018年04月25日 ページ情報: 英文 194 Pages
概要

当レポートでは、世界のギラン・バレー症候群市場について調査し、市場の現状と成長予測、治療別、投与ルート別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • 概要
  • 市場規模予測
  • 市場見通し
  • 主な市場発展
  • ポーターズファイブフォース分析
  • 大手3社の成功因子
  • 疾患概要
  • 主な合併・買収
  • パイプライン分析
  • 主な研究機関

第5章 市場動向

  • 促進因子
  • 阻害因子
  • 機会分析
  • 機会

第6章 治療別市場分析

  • イントロダクション
  • 市場価値シェア分析
  • 市場分析
  • 市場の魅力度分析

第7章 投与ルート別市場分析

  • イントロダクション
  • 市場価値シェア分析
  • 市場分析
  • 市場の魅力度分析

第8章 流通チャネル別市場分析

  • イントロダクション
  • 市場価値シェア分析
  • 市場分析
  • 市場の魅力度分析

第9章 地域別市場分析

  • 市場概要
  • 市場価値シェア分析
  • 市場予測
  • 市場分析
  • 市場の魅力度分析

第10章 北米市場

第11章 欧州市場

第12章 アジア太平洋地域市場

第13章 その他の諸国

第14章 企業プロファイル

  • 市場シェア分析
  • 競合マトリクス
  • 企業プロファイル
    • Grifols S.A.
    • CSL Behring LLC
    • Shire plc
    • Octapharma AG
    • 日本製薬株式会社
    • Akari Therapeutics, PLC
    • China Biologic Products Holdings, Inc.
    • Biotest AG
    • Kedrion s.p.A.
図表

List of Tables

  • TABLE 1 Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 2 Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 3 Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 4 Global Guillain-Barre Syndrome Market Value (US$ Mn) Forecast, by Region, 2015-2025
  • TABLE 5 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • TABLE 6 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 7 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 8 North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 9 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 10 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 11 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 12 Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 13 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 14 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 15 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 16 Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • TABLE 17 Rest of World Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015-2025
  • TABLE 18 Rest of World Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015-2025
  • TABLE 19 Rest of World Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Figure 01: Global Guillain-Barre Syndrome Market Snapshot
  • Figure 02: Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
  • Figure 03: Global Guillain-Barre Syndrome Market Opportunity Map, 2016
  • Figure 04: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 05: Guillain-Barre Syndrome Market Value Share, by Therapeutics (2016)
  • Figure 06: Guillain-Barre Syndrome Market Value Share, by Route of Administration (2016)
  • Figure 07: Guillain-Barre Syndrome Market Value Share, by Distribution Channel (2016)
  • Figure 08: Key Industry Developments
  • Figure 09: Key Market Developments
  • Figure 10: Porter's Five Forces
  • Figure 11: Key Success Factors of Top 3 Players
  • Figure 12: Global Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 13: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Intravenous Immunoglobulin, 2015-2025
  • Figure 14: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Plasma Exchange, 2015-2025
  • Figure 15: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015-2025
  • Figure 16: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2017-2025
  • Figure 17: Global Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 18: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Oral, 2015-2025
  • Figure 19: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Parenteral, 2015-2025
  • Figure 20: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2017-2025
  • Figure 21: Global Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 22: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2015-2025
  • Figure 23: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Retail Pharmacies, 2015-2025
  • Figure 24: Global Guillain-Barre Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015-2025
  • Figure 25: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 26: Global Guillain-Barre Syndrome Market Value Share, by Region, 2017 and 2025
  • Figure 27: Global Guillain-Barre Syndrome Market Attractiveness, by Region, 2017-2025
  • Figure 28: North America Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 29: North America Guillain-Barre Syndrome Market Value Share, by Country, 2017 and 2025
  • Figure 30: North America Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 31: North America Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 32: North America Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 33: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2017-2025
  • Figure 34: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2017-2025
  • Figure 35: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 36: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 37: Europe Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 38: Europe Guillain-Barre Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 39: Europe Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 40: Europe Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 41: Europe Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 42: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2017-2025
  • Figure 43: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2017-2025
  • Figure 44: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017-2025
  • Figure 45: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 46: Asia Pacific Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 47: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 48: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 49: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 50: Asia Pacific Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 51: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Therapeutics, 2017-2025
  • Figure 52: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Route of Administration, 2017-2025
  • Figure 53: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 54: Asia Pacific Guillain-Barre Syndrome Market Attractiveness, by Country/Sub-region, 2017-2025
  • Figure 55: Rest of World Guillain-Barre Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 56: Rest of World Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 57: Rest of World Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 58: Rest of World Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 59: Rest of World Guillain-Barre Syndrome Market Attractiveness, by Therapeutics, 2017-2025
  • Figure 60: Rest of World Guillain-Barre Syndrome Market Attractiveness, by Route of Administration, 2017-2025
  • Figure 61: Rest of World Guillain-Barre Syndrome Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 62: Global Guillain-Barre Syndrome Market Share Analysis, by Company (2016)
  • Figure 63: Shire plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 64: Shire plc Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 65: Shire plc Breakdown of Net Sales (%), by Geography, 2017
  • Figure 66: CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 67: CSL Behring LLC Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 68: CSL Behring LLC Breakdown of Net Sales (%), by Geography, 2016
  • Figure 69: Grifols, S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 70: Grifols, S.A. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 71: Grifols, S.A. Breakdown of Net Sales (%), by Region, 2016
  • Figure 72: Octapharma AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 73: Octapharma AG: R&D Expenses (US$ Mn), 2014-2017
  • Figure 74: Nihon Pharmaceutical Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 75: Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 76: Takeda Pharmaceutical Company Limited Breakdown of Ethical Drugs: Revenue (%), by Region, 2016
  • Figure 77: China Biologic Products Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 78: China Biologic Products Holdings, Inc. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 79: Biotest AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 80: Biotest AG Breakdown of Net Sales (%), by Region, 2016
  • Figure 81: Biotest AG Breakdown of Net Sales (%), by Business Segment, 2016
  • Figure 82: Kedrion S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 83: Kedrion S.p.A. Breakdown of Net Sales (%), by Region, 2016
  • Figure 84: Kedrion S.p.A. Breakdown of Net Sales (%), by Business Segment, 2016
目次

Guillain-Barre Syndrome Market - Overview:

This report on the global Guillain-Barre syndrome market studies the current as well as future prospects of the market globally. Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain-Barre syndrome as well as new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain-Barre syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.

Based on therapeutics, the Guillain-Barre syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain-Barre syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain-Barre syndrome and available treatment options for Guillain-Barre syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain-Barre syndrome market and that could also influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies. The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain-Barre syndrome market.

Geographically, the global Guillain-Barre syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides the market size and forecast for major countries in the respective region. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter's five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain-Barre syndrome market.

Key players operating in the global Guillain-Barre syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.

The global Guillain-Barre syndrome market has been segmented as follows:

Global Guillain-Barre Syndrome Market, by Therapeutics

  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others (Analgesics, Anticonvulsants, LMWH, etc.)

Global Guillain-Barre Syndrome Market, by Route of Administration

  • Oral
  • Parenteral

Global Guillain-Barre Syndrome Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others (Home Care, Clinics, etc.)

Global Guillain-Barre Syndrome Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • ASEAN
    • India
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of World

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution, by Geography, 2017 and 2025
  • 3.2. Global Guillain-Barre Syndrome Market Snapshot, 2016
  • 3.3. Global Guillain-Barre Syndrome Market: Opportunity Map

4. Market Overview

  • 4.1. Overview
  • 4.2. Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, 2015-2025
  • 4.3. Global Guillain-Barre Syndrome Market Outlook
  • 4.4. Global Guillain-Barre Syndrome Market: Key Market Developments
  • 4.5. Global Guillain-Barre Syndrome Market: Porter's Five Forces
  • 4.6. Global Guillain-Barre Syndrome Market: Key Success Factors of Top 3 Players
  • 4.7. Guillain-Barre Syndrome: Disease Overview
    • 4.7.1. Therapeutics
    • 4.7.2. Epidemiology
    • 4.7.3. Symptoms
    • 4.7.4. Etiology
    • 4.7.5. Pathophysiology
    • 4.7.6. Diagnosis
  • 4.8. Global Guillain-Barre Syndrome Market: Key Mergers & Acquisitions
  • 4.9. Guillain-Barre Syndrome: Pipeline Analysis
  • 4.10. Guillain-Barre Syndrome: Major Research Institutes Involved

5. Market Dynamics

  • 5.1. Drivers
  • 5.2. Restraints
  • 5.3. Opportunity Analysis
  • 5.4. Opportunities

6. Guillain-Barre Syndrome Market Analysis, by Therapeutics

  • 6.1. Introduction
  • 6.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 6.3. Guillain-Barre Syndrome Market Analysis, by Therapeutics
    • 6.3.1. Intravenous Immunoglobulin
    • 6.3.2. Plasma Exchange
    • 6.3.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 6.4. Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics

7. Guillain-Barre Syndrome Market Analysis, by Route of Administration

  • 7.1. Introduction
  • 7.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 7.3. Guillain-Barre Syndrome Market Analysis, by Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration

8. Guillain-Barre Syndrome Market Analysis, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 8.3. Guillain-Barre Syndrome Market Analysis, by Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others (Home Care, Clinics, etc.)
  • 8.4. Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel

9. Guillain-Barre Syndrome Market Analysis, by Region

  • 9.1. Global Guillain-Barre Syndrome Market Snapshot, by Country
  • 9.2. Global Guillain-Barre Syndrome Market Value Share Analysis, by Region
  • 9.3. Global Guillain-Barre Syndrome Market Forecast, by Region
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Rest of World
  • 9.4. Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Region
  • 9.5. Key Market Trends, by Region

10. North America Guillain-Barre Syndrome Market Analysis

  • 10.1. Key Findings
  • 10.2. North America Guillain-Barre Syndrome Market Overview
  • 10.3. North America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 10.4. North America Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 10.4.1. Intravenous Immunoglobulin
    • 10.4.2. Plasma Exchange
    • 10.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 10.5. North America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 10.6. North America Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 10.6.1. Oral
    • 10.6.2. Parenteral
  • 10.7. North America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 10.8. North America Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 10.8.1. Hospital Pharmacies
    • 10.8.2. Retail Pharmacies
    • 10.8.3. Others (Home Care, Clinics, etc.)
  • 10.9. North America Guillain-Barre Syndrome Market Analysis, by Country
  • 10.10. North America Guillain-Barre Syndrome Market Value Share Analysis, by Country
  • 10.11. North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2017-2025
    • 10.11.1. U.S.
    • 10.11.2. Canada
  • 10.12. North America Guillain-Barre Syndrome Market Attractiveness Analysis
    • 10.12.1. By Therapeutics
    • 10.12.2. By Route of Administration
    • 10.12.3. By Distribution Channel
    • 10.12.4. By Country

11. Europe Guillain-Barre Syndrome Market Analysis

  • 11.1. Key Findings
  • 11.2. Europe Guillain-Barre Syndrome Market Overview
  • 11.3. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 11.4. Europe Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 11.4.1. Intravenous Immunoglobulin
    • 11.4.2. Plasma Exchange
    • 11.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 11.5. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 11.6. Europe Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 11.6.1. Oral
    • 11.6.2. Parenteral
  • 11.7. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 11.8. Europe Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Others (Home Care, Clinics, etc.)
  • 11.9. Europe Guillain-Barre Syndrome Market Analysis, by Country/Sub-region
  • 11.10. Europe Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region
  • 11.11. Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
    • 11.11.1. U.K.
    • 11.11.2. Germany
    • 11.11.3. Italy
    • 11.11.4. France
    • 11.11.5. Spain
    • 11.11.6. Rest of Europe
  • 11.12. Europe Guillain-Barre Syndrome Market Attractiveness Analysis
    • 11.12.1. By Therapeutics
    • 11.12.2. By Route of Administration
    • 11.12.3. By Distribution Channel
    • 11.12.4. By Country/Sub-region

12. Asia Pacific Guillain-Barre Syndrome Market Analysis

  • 12.1. Key Findings
  • 12.2. Asia Pacific Guillain-Barre Syndrome Market Overview
  • 12.3. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 12.4. Asia Pacific Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 12.4.1. Intravenous Immunoglobulin
    • 12.4.2. Plasma Exchange
    • 12.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 12.5. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 12.6. Asia Pacific Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 12.6.1. Oral
    • 12.6.2. Parenteral
  • 12.7. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 12.8. Asia Pacific Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Others (Home Care, Clinics, etc.)
  • 12.9. Asia Pacific Guillain-Barre Syndrome Market Analysis, by Country/Sub-region
  • 12.10. Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region
  • 12.11. Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
    • 12.11.1. China
    • 12.11.2. Japan
    • 12.11.3. India
    • 12.11.4. ASEAN
    • 12.11.5. Rest of Asia Pacific
  • 12.12. Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis
    • 12.12.1. By Therapeutics
    • 12.12.2. By Route of Administration
    • 12.12.3. By Distribution Channel
    • 12.12.4. By Country/Sub-region

13. Rest of World Guillain-Barre Syndrome Market Analysis

  • 13.1. Key Findings
  • 13.2. Rest of World Guillain-Barre Syndrome Market Overview
  • 13.3. Rest of World Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics
  • 13.4. Rest of World Guillain-Barre Syndrome Market Forecast, by Therapeutics
    • 13.4.1. Intravenous Immunoglobulin
    • 13.4.2. Plasma Exchange
    • 13.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
  • 13.5. Rest of World Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration
  • 13.6. Rest of World Guillain-Barre Syndrome Market Forecast, by Route of Administration
    • 13.6.1. Oral
    • 13.6.2. Parenteral
  • 13.7. Rest of World Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel
  • 13.8. Rest of World Guillain-Barre Syndrome Market Forecast, by Distribution Channel
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Others (Home Care, Clinics, etc.)
  • 13.9. Rest of World Guillain-Barre Syndrome Market Attractiveness Analysis
    • 13.9.1. By Therapeutics
    • 13.9.2. By Route of Administration
    • 13.9.3. By Distribution Channel

14. Company Profiles

  • 14.1. Global Guillain-Barre Syndrome Market Share Analysis, by Company, 2016
  • 14.2. Competition Matrix
  • 14.3. Company Profiles
    • 14.3.1. Grifols S.A.
      • 14.3.1.1. Company Details
      • 14.3.1.2. Business Overview
      • 14.3.1.3. Strategic Overview
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. CSL Behring LLC
      • 14.3.2.1. Company Details
      • 14.3.2.2. Business Overview
      • 14.3.2.3. Strategic Overview
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Shire plc
      • 14.3.3.1. Company Details
      • 14.3.3.2. Business Overview
      • 14.3.3.3. Strategic Overview
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Octapharma AG
      • 14.3.4.1. Company Details
      • 14.3.4.2. Business Overview
      • 14.3.4.3. Strategic Overview
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Nihon Pharmaceutical Co., Ltd.
      • 14.3.5.1. Company Details
      • 14.3.5.2. Business Overview
      • 14.3.5.3. Strategic Overview
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Akari Therapeutics, PLC
      • 14.3.6.1. Company Details
      • 14.3.6.2. Business Overview
      • 14.3.6.3. Strategic Overview
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. China Biologic Products Holdings, Inc.
      • 14.3.7.1. Company Details
      • 14.3.7.2. Business Overview
      • 14.3.7.3. Strategic Overview
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Biotest AG
      • 14.3.8.1. Company Details
      • 14.3.8.2. Business Overview
      • 14.3.8.3. Strategic Overview
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Kedrion s.p.A.
      • 14.3.9.1. Company Details
      • 14.3.9.2. Business Overview
      • 14.3.9.3. Strategic Overview
      • 14.3.9.4. SWOT Analysis